Skin Neoplasms Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Skin Neoplasms Epidemiology Forecast Report Coverage

Expert Market Research's “Skin Neoplasms Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of skin neoplasms. It projects the future incidence and prevalence rates of skin neoplasms cases across various populations. The study covers age, gender, and type as major determinants of the skin neoplasms population. The report highlights patterns in the prevalence of skin neoplasms over time and projects future trends based on multiple variables.

Skin Neoplasms Understanding: Disease Overview

Skin neoplasms include benign and malignant proliferations of skin cells, primarily keratinocytes and melanocytes. The most prevalent forms are basal cell carcinoma, squamous cell carcinoma, and melanoma. Ultraviolet radiation, genetic predisposition, and immunosuppression are major etiological factors. Incidence rates have risen globally due to increased sun exposure and improved detection. Early identification remains crucial, as prognosis varies widely depending on tumor type and depth of invasion. Non-melanoma skin cancers account for most cases but have high survival rates when detected early.

Skin Neoplasms Epidemiology Perspective

The skin neoplasms epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the skin neoplasms epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for skin neoplasms and their trends. The skin neoplasms detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Skin neoplasms are among the most common cancers worldwide.
• In 2022, approximately 331,722 new cases of cutaneous melanoma were diagnosed worldwide, resulting in about 58,667 deaths globally.
• Globally, an estimated 1,234,533 new cases of non-melanoma skin neoplasms (primarily basal and squamous cell carcinomas) were recorded in 2022, reflecting their substantial global burden.
• Globally, males accounted for 57% (151,921 of 267,353) of ultraviolet radiation-attributable cutaneous melanomas, indicating a higher disease burden among men for UV-related skin neoplasms.
• After young adulthood (where females may have higher melanoma incidence), incidence becomes higher in males than females in most regions.

Read more about this report - Request a Free Sample

Country-wise Skin Neoplasms Epidemiology Segment

The skin neoplasms epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, skin neoplasms remain a significant public health concern, reflecting both high sun exposure and aging demographics. According to the American Cancer Society, approximately 104,960 new invasive melanoma cases are expected in 2025, including about 60,550 men and 44,410 women. Additionally, non-melanoma skin cancers such as basal and squamous cell carcinoma affect an estimated 5.4 million cases in 3.3 million individuals annually. While women under 50 exhibit higher melanoma incidence, rates rise sharply in older men. Continued awareness and early detection remain essential to reducing the disease’s growing national burden.

Skin Neoplasms: Treatment Overview

The treatment depends on tumor type, stage, and location. Surgical excision remains the standard for most skin neoplasms, with Mohs micrographic surgery preferred for high-risk or recurrent lesions. Nonsurgical approaches, cryotherapy, photodynamic therapy, and topical agents are used for superficial cancers. Advanced melanomas may require immunotherapies like checkpoint inhibitors or targeted therapies such as BRAF and MEK inhibitors. Radiation therapy and chemotherapy are reserved for inoperable or metastatic cases. Continued advancements in immuno-oncology and targeted molecular therapy have improved outcomes in advanced-stage disease.

Key Questions Answered

• What are the key findings of skin neoplasms epidemiology in the 8 major markets?
• What will be the total number of patients with skin neoplasms across the 8 major markets during the forecast period?
• What was the country-wise skin neoplasms epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of skin neoplasms during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of skin neoplasms during the forecast period of 2026-2035?
• What are the currently available treatments for skin neoplasms?
• What are the disease risks, signs, symptoms, and unmet needs of skin neoplasms?

Scope of the Skin Neoplasms Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of skin neoplasms based on several factors.
• Skin Neoplasms Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The skin neoplasms report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Bone Neoplasm Pipeline Analysis

Uveal Neoplasms Market